ADVFN - Advanced Financial Network.
HOME» NYSE » D » DD Stock Price » DD Stock News

Du Pont E I De Nem Share News

 Du Pont (e.i.) De Nemours & Stock Price
DD Stock Price
 Du Pont (e.i.) De Nemours & Stock Chart
DD Stock Chart
 Du Pont (e.i.) De Nemours & Stock News
DD Stock News
 Du Pont (e.i.) De Nemours & Company Information
DD Company Information
 Du Pont (e.i.) De Nemours & Stock Trades
DD Stock Trades

Jury Awards $1 Billion to Monsanto in Suit Against DuPont

A federal jury Wednesday awarded $1 billion to Monsanto Co. (MON) in a patent-infringement lawsuit against rival DuPont Co. (DD) over Monsanto's Roundup Ready seed technology. The jury reached the verdict at a St. Louis federal courthouse on the same day that it started deliberations. The trial began July 9. The jury found DuPont willfully infringed Monsanto's patent for Roundup Ready seeds and awarded $1 billion in damages to Monsanto, according to a statement from Monsanto on Wednesday evening. Roundup Ready seeds grow into plants able to survive exposure to glyphosate, the active ingredient in the Roundup weedkiller made by Monsanto. St. Louis-based Monsanto filed suit in 2009 over DuPont's Optimum GAT soybean seed, which included a DuPont transgenic trait that enabled the crop to withstand applications of glyphosate. DuPont and its seed subsidiary, Pioneer Hi-Bred, initially marketed the seed as an alternative to Monsanto's Roundup Ready, but ultimately paired the Monsanto trait with its own trait in the Optimum GAT product. Monsanto, the world's largest seed company, claimed that by stacking the gene onto its own product, DuPont violated the terms of a 2002 licensing agreement. DuPont countersued, alleging anticompetitive practices. DuPont has since shelved the Optimum GAT product. During the trial, DuPont, based in Wilmington, Del., argued that Monsanto misled U.S. government officials to obtain the patent. "This verdict highlights that all companies that make early and substantial investments in developing cutting-edge technology will have their intellectual property rights upheld and fairly valued," said David Snively, Monsanto's Executive Vice President and General Counsel, in a prepared statement. Monsanto's Roundup Ready technology is used broadly by farmers, as the company has licensed it to other companies. The glyphosate-resistant trait is used in alfalfa, corn, cotton, canola and sugar beets. Write to David Kesmodel at Subscribe to WSJ:

Stock News for Du Pont E I De Nem (DD)
11/13/201506:30:00Syngenta Shares Rise on Takeover Report
11/10/201517:23:52Statement of Changes in Beneficial Ownership (4)
11/10/201509:25:00DuPont Digital Printing Collaborates With EFI Reggiani to Deliver...
11/10/201503:03:00DuPont Names Breen CEO
11/09/201517:27:56Current Report Filing (8-k)
11/09/201515:05:00DuPont Names Breen CEO, Removing Interim Tag--Update
11/09/201508:20:00DuPont Names Breen CEO, Removing Interim Tag
11/09/201508:03:00DuPont Names Breen CEO, Removing Interim Tag
11/09/201506:45:00DuPont Board of Directors Names Edward D. Breen Chair and CEO
11/06/201503:02:00Farm Giants Explore Deals
11/05/201516:40:00Agricultural Giants Look to Join Forces
11/05/201516:25:00Agricultural Giants Look to Join Forces
11/03/201515:40:00Monsanto, Deere Join Forces Over Data Services
11/02/201509:45:00DuPont Announces Business Unit Consolidations and Leadership...
11/01/201503:15:25Splitsville: Activist Investing Daily
10/30/201519:22:18DuPont opens $225M cellulosic ethanol plant
10/29/201503:07:01Activist Investing Daily: Large Caps
10/27/201510:27:00DuPont Profit Slides on Weak Ag Market, Strong Dollar -- Update
10/27/201507:38:50Current Report Filing (8-k)
10/27/201507:30:00DuPont Profit Drops on Headwinds

Du Pont E I De Nem and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations